Regulatory Focus™ > News Articles > Europe: European Medicines Agency Adopts Two Alzheimers Biomarkers

Europe: European Medicines Agency Adopts Two Alzheimers Biomarkers

Posted 05 April 2012 | By Ansis Helmanis

Under a voluntary new scientific pathway, the European Medicines Agency (EMA) adopted two innovative biomarkers for use in the development of new medications for Alzheimers submitted by Bristol-Myers Squibb: PET amyloid imaging (positive/ negative) as a biomarker for enrichment for use in predementia AD clinical trials, and use of CSF AB 1-42 and t-tau and/or PET-amyloid imaging (positive/ negative).

The new process can lead to either a Committee for Medicinal Products for Human Use (CHMP) opinion or a Scientific Advice and is open to biomarkers developed by consortia, networks, public/private partnerships, learned societies or pharmaceutical industry for a specific intended use in pharmaceutical research and development. 


Read more:

PET amyloid imaging (positive/ negative) as a biomarker for enrichment for use in predementia AD clinical trials

CSF AB 1-42 and t-tau and/or PET-amyloid imaging (positive/ negative)

More Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe